United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$331.59 USD
-5.15 (-1.53%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $331.56 -0.03 (-0.01%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth C Momentum A VGM
Brokerage Reports
0 items in cart
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 161 - 180 ( 598 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Treprostinil/IPF: FDA Grants ODD; On-Track to Start Ph3 TETON Study in 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Evolving PAH and Lung Disease Platform Presents Several Paths Yet to Be Distinguished
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Strong Q3, Plenty of Cash and Positive 2021 Outlook
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso? Safety Data at CHEST 2020 Adds Momentum to Catalyst-Rich 2021 (Erratum)
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
PTAB Decision Paves Way for TreT First-to-Market; Pivotal Data/Filing in Q1:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso?/PH-ILD sNDA Acceptance Setting Up Expansion Opportunity
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Potential Drivers for Platform Growth Abound, But Our Focus Remains on Execution; Reit Neutral and $125 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q2 Revenue Beat Amid COVID-19; Poised for Long-Term Success
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department